The U.S. biotech big Illumina has been slapped with a $475 million superb for getting cancer-screening firm Grail with out regulators’ approval, the European Union
The U.S. biotech big Illumina has been slapped with a $475 million superb for getting cancer-screening firm Grail with out regulators’ approval, the European Union